Related Experiment Video
Updated: Jun 2, 2026
10:58
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
De Novo Protein Design Enables Targeting of Intractable Oncogenic Protein-Protein Interfaces
Varshika Ram Prakash1,2, Yusuf Najy1,2, Kalel Garrett1,2
1Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Biologics (Basel, Switzerland)
|June 1, 2026
Summary
This study introduces DesignForge, a computational tool for designing novel protein binders that target cancer-driving protein interactions. The framework successfully generated promising de novo miniprotein designs for key oncogenic interfaces.
Area of Science:
- Computational biology
- Structural biology
- Protein engineering
Background:
- Protein-protein interactions (PPIs) involving oncogenic drivers are challenging cancer targets.
- Conventional therapies face limitations in targeting these PPIs effectively.
Purpose of the Study:
- To develop an integrated computational framework for designing de novo miniprotein binders.
- To target hotspot residues within oncogenic protein-protein interfaces.
Main Methods:
- DesignForge pipeline integrates hotspot identification, generative backbone design, and structural validation.
- Utilizes energetic analysis, BindCraft, ProteinMPNN, and AlphaFold2.
- Applied to PD-1/PD-L1, MYC/MAX, and KRAS/RAF interfaces.
Main Results:
- Generated designs show high structural confidence and favorable interface energetics.
- Computational models predict compatible conformations for PD-1, MYC/MAX, and KRAS binders.
- Confirmed engagement of key hotspot residues in silico.
Conclusions:
- DesignForge offers a reproducible framework for hotspot-guided de novo protein binder design.
- The study presents computational predictions requiring experimental validation.
- This approach holds potential for targeting difficult oncogenic PPIs.
Keywords:
AlphaFold2Molecular Operating Environment (MOE)computational binder designde novo protein designhotspot mappingimmuno-oncologyoncogenic protein interfacesprotein–protein interactionstherapeutic biologicsMore Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
Related Concept Videos
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
02:04Protein-Protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
02:26Protein Networks
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...